|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aprea Therapeutics, Inc. (APRE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,990,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, a mutated gene in cancer. Co.'s main product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia. Co. is conducting several trials in hematologic malignancy indications, including a trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
5,500 |
5,500 |
48,090 |
64,820 |
| Total Buy Value |
$10,110 |
$10,110 |
$176,052 |
$298,013 |
| Total People Bought |
1 |
1 |
4 |
5 |
| Total Buy Transactions |
1 |
1 |
10 |
14 |
| Total Shares Sold |
0 |
0 |
6,462 |
6,462 |
| Total Sell Value |
$0 |
$0 |
$29,583 |
$29,583 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Peters Richard |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
3,119 |
|
- |
|
| Duey Marc |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
234,696 |
|
- |
|
| Henneman John B III |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
10,229 |
|
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
45,775 |
|
- |
|
| Grissinger Michael |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
2,889 |
|
- |
|
| Bizzari Jean-Pierre |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
1,045 |
|
- |
|
| Gruia Gabriela |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
1,045 |
|
- |
|
| Pamukcu Rifat |
Director |
– • – |
2025-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
5,446 |
|
- |
|
| Gilad Oren |
President/CEO |
• • – |
2025-04-03 |
4 |
B |
$1.80 |
$10,110 |
D/D |
5,500 |
345,620 |
2.81 |
- |
|
| Gilad Oren |
President/CEO |
• • – |
2025-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,725 |
340,120 |
|
- |
|
| Hamill John P. |
SrVP/CFO/Prin Fin & Acct Ofcr |
• – – |
2025-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,365 |
22,733 |
|
- |
|
| Gilad Oren |
President/CEO |
• • – |
2024-10-23 |
4 |
B |
$3.92 |
$1,958 |
D/D |
500 |
333,395 |
2.73 |
- |
|
| Duey Marc |
Director |
– • – |
2024-10-18 |
4 |
S |
$4.58 |
$29,583 |
D/D |
(6,462) |
233,651 |
|
- |
|
| Duey Marc |
Director |
– • – |
2024-10-16 |
4 |
B |
$4.39 |
$131,700 |
D/D |
30,000 |
240,113 |
2.39 |
- |
|
| Gilad Oren |
President/CEO |
• • – |
2024-10-15 |
4 |
B |
$2.90 |
$725 |
D/D |
250 |
332,895 |
2.73 |
- |
|
| Duey Marc |
Director |
– • – |
2024-10-14 |
4 |
B |
$2.58 |
$490 |
D/D |
190 |
210,113 |
2.31 |
- |
|
| Gilad Oren |
President/CEO |
• • – |
2024-10-14 |
4 |
B |
$2.59 |
$2,590 |
D/D |
1,000 |
332,645 |
2.73 |
- |
|
| Hamill John P. |
SrVP/CFO/Prin Fin & Acct Ofcr |
• – – |
2024-10-11 |
4 |
B |
$2.46 |
$123 |
D/D |
50 |
19,368 |
2.66 |
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2024-10-11 |
4 |
B |
$2.68 |
$26,800 |
D/D |
10,000 |
44,730 |
2.39 |
- |
|
| Hamill John P. |
SrVP/CFO/Prin Fin & Acct Ofcr |
• – – |
2024-10-10 |
4 |
B |
$2.61 |
$1,175 |
D/D |
450 |
19,318 |
2.66 |
- |
|
| Gilad Oren |
President/CEO |
• • – |
2024-10-10 |
4 |
B |
$2.54 |
$381 |
D/D |
150 |
331,645 |
2.73 |
- |
|
| Henneman John B III |
Director |
– • – |
2024-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
9,184 |
|
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2024-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
34,730 |
|
- |
|
| Grissinger Michael |
Director |
– • – |
2024-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
1,844 |
|
- |
|
| Pamukcu Rifat |
Director |
– • – |
2024-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,045 |
4,401 |
|
- |
|
154 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
